JP2025507542A5 - - Google Patents
Info
- Publication number
- JP2025507542A5 JP2025507542A5 JP2024547296A JP2024547296A JP2025507542A5 JP 2025507542 A5 JP2025507542 A5 JP 2025507542A5 JP 2024547296 A JP2024547296 A JP 2024547296A JP 2024547296 A JP2024547296 A JP 2024547296A JP 2025507542 A5 JP2025507542 A5 JP 2025507542A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- alkyl
- disorder
- cycloalkyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263313208P | 2022-02-23 | 2022-02-23 | |
| US63/313,208 | 2022-02-23 | ||
| PCT/US2023/063111 WO2023164536A1 (en) | 2022-02-23 | 2023-02-23 | Pyrazolyl compounds as kv7 channel activators |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025507542A JP2025507542A (ja) | 2025-03-21 |
| JP2025507542A5 true JP2025507542A5 (enExample) | 2025-11-19 |
Family
ID=87766731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024547296A Pending JP2025507542A (ja) | 2022-02-23 | 2023-02-23 | Ｋｖ７チャネル活性化剤としてのピラゾリル化合物 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20250171429A1 (enExample) |
| EP (1) | EP4482489A4 (enExample) |
| JP (1) | JP2025507542A (enExample) |
| KR (1) | KR20240151835A (enExample) |
| CN (1) | CN118695860A (enExample) |
| AU (1) | AU2023225024A1 (enExample) |
| CA (1) | CA3244500A1 (enExample) |
| IL (1) | IL314554A (enExample) |
| MX (1) | MX2024010078A (enExample) |
| WO (1) | WO2023164536A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023164537A1 (en) * | 2022-02-23 | 2023-08-31 | Biohaven Therapeutics Ltd. | Pyrazolyl compounds as kv7 channel activators |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1441724E (pt) * | 2001-09-27 | 2007-10-15 | Serono Lab | Métodos para aumentar os níveis endógenos de testosterona |
| AU2002363250A1 (en) * | 2001-11-01 | 2003-05-12 | Icagen, Inc. | Pyrazole-amides and-sulfonamides |
| WO2003039529A1 (en) * | 2001-11-07 | 2003-05-15 | 4Sc A.G. | Selective antibacterial agents |
| ATE410161T1 (de) * | 2003-05-02 | 2008-10-15 | Elan Pharm Inc | 4-bromo-5-(2-chloro-benzoylamino)-1h-pyrazol-3- carbonsäureamid-derivate und verwandte verbindungen als bradykinin b1 rezeptor antagonisten zur behandlung von entzündlichen erkrankungen |
| CA2525245C (en) * | 2003-06-27 | 2010-10-19 | Pfizer Products Inc. | Pyrazolo[3,4-b]pyridin-6-ones as gsk-3 inhibitors |
| WO2005048953A2 (en) * | 2003-11-13 | 2005-06-02 | Ambit Biosciences Corporation | Amide derivatives as kinase modulators |
| ES2317079T3 (es) * | 2003-12-24 | 2009-04-16 | Astrazeneca Ab | Pirimidinas con actividad tie2 (tek). |
| CA2592118C (en) * | 2004-12-23 | 2015-11-17 | Deciphera Pharmaceuticals, Llc | Urea derivatives as enzyme modulators |
| DOP2006000233A (es) * | 2005-10-28 | 2007-06-15 | Lilly Co Eli | Inhibidores de cinasa |
| PL2510925T3 (pl) * | 2006-02-15 | 2017-03-31 | Dendreon Pharmaceuticals, Inc. | Drobnocząsteczkowe modulatory aktywności trp-p8 |
| ES2351274T3 (es) * | 2007-06-06 | 2011-02-02 | Torrent Pharmaceuticals Ltd | Nuevos compuestos. |
| US8486987B2 (en) * | 2007-11-16 | 2013-07-16 | University Of Medicine And Dentistry Of New Jersey | Mechanism-based small-molecule parasite inhibitors |
| AU2009226136B2 (en) * | 2008-03-17 | 2013-08-15 | Ambit Biosciences Corporation | Quinazoline derivatives as RAF kinase modulators and methods of use thereof |
| CA2724413C (en) * | 2008-05-15 | 2016-10-18 | Duke University | Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof |
| US9315449B2 (en) * | 2008-05-15 | 2016-04-19 | Duke University | Substituted pyrazoles as heat shock transcription factor activators |
| CN103619171B (zh) * | 2010-11-03 | 2015-11-25 | 陶氏益农公司 | 杀虫组合物和与其相关的方法 |
| US9227976B2 (en) * | 2012-10-25 | 2016-01-05 | Usher Iii Initiative, Inc. | Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome |
| CA2891334C (en) * | 2012-11-13 | 2021-10-19 | Array Biopharma Inc. | Bicyclic urea, thiourea, guanidine and cyanoguanidine compounds useful for the treatment of pain |
| US9822118B2 (en) * | 2012-11-13 | 2017-11-21 | Array Biopharma Inc. | Bicyclic heteroaryl urea, thiourea, guanidine and cyanoguanidine compounds as TrkA kinase inhibitors |
| US9067894B1 (en) * | 2013-03-07 | 2015-06-30 | Vanderbilt University | Compound, composition, and method of activating GIRK potassium channel and use of same for treating conditions of interest |
| EP3558992A4 (en) * | 2016-12-15 | 2020-12-02 | ONO Pharmaceutical Co., Ltd. | TREK CHANNEL ACTIVATOR (K + CHANNELS ASSOCIATED WITH TWIK) |
| PH12021553058A1 (en) * | 2019-06-06 | 2022-07-25 | Hutchison Medipharma Ltd | Tricyclic compounds and their use |
-
2023
- 2023-02-23 CN CN202380021419.2A patent/CN118695860A/zh active Pending
- 2023-02-23 IL IL314554A patent/IL314554A/en unknown
- 2023-02-23 US US18/839,858 patent/US20250171429A1/en active Pending
- 2023-02-23 MX MX2024010078A patent/MX2024010078A/es unknown
- 2023-02-23 WO PCT/US2023/063111 patent/WO2023164536A1/en not_active Ceased
- 2023-02-23 KR KR1020247031504A patent/KR20240151835A/ko active Pending
- 2023-02-23 CA CA3244500A patent/CA3244500A1/en active Pending
- 2023-02-23 AU AU2023225024A patent/AU2023225024A1/en active Pending
- 2023-02-23 EP EP23760908.6A patent/EP4482489A4/en active Pending
- 2023-02-23 JP JP2024547296A patent/JP2025507542A/ja active Pending
-
2025
- 2025-04-01 US US19/097,371 patent/US20250230152A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101784533B (zh) | 4-苄基氨基喹啉、含有它们的药物组合物和它们在治疗中的用途 | |
| JP2025501629A5 (enExample) | ||
| JP2025501630A5 (enExample) | ||
| CN103189337A (zh) | 氨基二氢化茚衍生物、包含所述氨基二氢化茚衍生物的药物组合物及其在治疗中的用途 | |
| JP2021518844A5 (enExample) | ||
| US8937065B2 (en) | Compositions and methods for modulating a kinase | |
| US8815914B2 (en) | Positive allosteric modulators of nicotinic acetylcholine receptor | |
| ME01903B (me) | Hetrociklički sulfonamidi, njihova upotreba i farmaceutski pripravci | |
| CA2840627A1 (en) | Quinazolines as therapeutic compounds and related methods of use | |
| JP2010505794A5 (enExample) | ||
| CN103237788A (zh) | 苯烷基胺衍生物、包含所述苯烷基胺衍生物的药物组合物及其在治疗中的用途 | |
| CN101541753B (zh) | 作为5-ht(5a)受体拮抗剂的2-氨基喹啉类化合物 | |
| JP2023523402A (ja) | スピロウレア誘導体 | |
| JP2025507543A5 (enExample) | ||
| TW201414730A (zh) | 菸鹼乙醯膽鹼受體之新穎正向異位調節劑 | |
| RU2013124827A (ru) | Производные индола и способ их получения | |
| JP2017502069A5 (enExample) | ||
| JP2025111422A (ja) | イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物 | |
| US20250230152A1 (en) | Pyrazolyl compounds as kv7 channel activators | |
| JP2008266321A (ja) | フェニレンジアミン誘導体を有効成分とする眼圧下降剤 | |
| WO2014006120A1 (en) | New positive allosteric modulators of nicotinic acetylcholine receptor | |
| RU2004117091A (ru) | Соль лимонной кислоты терапевтического соединения и фармацевтические композиции на ее основе | |
| WO2024054807A1 (en) | Combination therapies including metal channel activators and tdp-43 modulators | |
| JP2003507323A (ja) | １，４−ジアザシクロヘプタン化合物、その製造方法およびその薬剤としての使用 | |
| CN109912514A (zh) | (2-杂芳基胺基苯基)氮杂环衍生物及其用途 |